#USA #New York #Pomerantz Law #SEC Investigation #Regencell Bioscience

Investigation Launched by Pomerantz Law Firm for Regencell Investors

On November 20, 2025, Pomerantz LLP announced that it has initiated an inquiry on behalf of investors of Regencell Bioscience Holdings Limited, a company trading under the NASDAQ symbol RGC. The law firm aims to determine if Regencell or its executives have committed securities fraud or other inappropriate business practices.

The catalyst for this investigation stems from a recent filing by Regencell with the U.S. Securities and Exchange Commission (SEC) on October 31, 2025. The company revealed that it had received a subpoena from the U.S. Department of Justice (DOJ) amid volatility in its share market. The DOJ’s inquiry revolves around the trading activities of Regencell’s shares, indicating potential illegal practices that could have harmed investors.

In the filing, Regencell disclosed that the DOJ requested a wide range of documents linked to their corporate operations, financial dealings, and accounting matters. Regencell also warned that it would likely incur massive legal fees related to the investigation, with potential liabilities that could exceed its available insurance coverage. As a result of this troubling news, the stock price for Regencell plummeted by 18.56%, dropping from $16.65 to $13.56 per share by November 3, 2025.

Pomerantz, known for its strength in corporate, securities, and antitrust class action litigation, has a longstanding history in advocating for investors who have fallen victim to mismanagement and fraud. Founded by the late Abraham L. Pomerantz, a pioneer in securities class actions, the firm has secured many multimillion-dollar settlements on behalf of aggrieved investors.

The investigation’s outcome could significantly affect Regencell’s stock performance and financial standing, especially if it results in major legal penalties or settlements. Investors are encouraged to monitor the situation closely and consider their options.

For those interested in learning more about joining a potential class action lawsuit, Pomerantz has made available contact information for their attorney, Danielle Peyton, who can provide insights into the ongoing investigation. Investors who believe their financial interests may have been compromised can reach out directly via email at [email protected] or by phone at 646-581-9980, extension 7980.

In light of these developments, Regencell shareholders should reassess their positions and stay informed about any new data from Pomerantz LLP. Depending on the investigation's findings, substantial ramifications could be on the horizon for Regencell and its investors. As this situation unfolds, the actions taken by both the DOJ and Regencell may redefine investor trust and corporate governance standards in the biotech and health sectors.